Deciphera Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Deciphera Pharmaceuticals's earnings have been declining at an average annual rate of -5.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 46.1% per year.
Key information
-5.5%
Earnings growth rate
8.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 46.1% |
| Return on equity | -55.6% |
| Net Margin | -119.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Deciphera Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 163 | -195 | 136 | 0 |
| 30 Sep 23 | 151 | -194 | 130 | 0 |
| 30 Jun 23 | 144 | -187 | 126 | 0 |
| 31 Mar 23 | 138 | -182 | 123 | 0 |
| 31 Dec 22 | 134 | -179 | 120 | 0 |
| 30 Sep 22 | 122 | -221 | 121 | 0 |
| 30 Jun 22 | 109 | -258 | 127 | 0 |
| 31 Mar 22 | 100 | -286 | 130 | 0 |
| 31 Dec 21 | 96 | -300 | 132 | 0 |
| 30 Sep 21 | 91 | -274 | 129 | 0 |
| 30 Jun 21 | 84 | -258 | 124 | 0 |
| 31 Mar 21 | 67 | -255 | 121 | 0 |
| 31 Dec 20 | 42 | -266 | 114 | 0 |
| 30 Sep 20 | 23 | -271 | 108 | 0 |
| 30 Jun 20 | 7 | -263 | 96 | 0 |
| 31 Mar 20 | 25 | -218 | 76 | -36 |
| 31 Dec 19 | 25 | -192 | 66 | 0 |
| 30 Sep 19 | 25 | -157 | 48 | 27 |
| 30 Jun 19 | 25 | -126 | 36 | 48 |
| 31 Mar 19 | 0 | -126 | 29 | 102 |
| 31 Dec 18 | 0 | -100 | 21 | 0 |
| 30 Sep 18 | 0 | -87 | 19 | 71 |
| 30 Jun 18 | 0 | -75 | 17 | 60 |
| 31 Mar 18 | 0 | -64 | 14 | 51 |
| 31 Dec 17 | 0 | -50 | 11 | 40 |
| 30 Sep 17 | 0 | -39 | 9 | 30 |
| 30 Jun 17 | 0 | -33 | 8 | 25 |
| 31 Mar 17 | 0 | -28 | 7 | 22 |
| 31 Dec 16 | 0 | -26 | 6 | 20 |
Quality Earnings: D05 is currently unprofitable.
Growing Profit Margin: D05 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: D05 is unprofitable, and losses have increased over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare D05's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: D05 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: D05 has a negative Return on Equity (-55.55%), as it is currently unprofitable.